Working... Menu
Trial record 95 of 157 for:    eribulin

An Open-Label Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01418677
Recruitment Status : Completed
First Posted : August 17, 2011
Last Update Posted : May 17, 2016
Information provided by (Responsible Party):
Eisai Inc.

Brief Summary:
This is an open-label non-randomized study in subjects with advanced or metastatic solid tumors who are no longer responding to available therapy. HALAVEN will be administered to subjects on Days 1 and 8 of a 21-day cycle.

Condition or disease Intervention/treatment Phase
Unspecified Adult Solid Tumor, Protocol Specific Drug: E7389 Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label Phase 1 Study to Assess the Pharmacokinetics and Safety of HALAVEN in Subjects With Cancer Who Also Have Impaired Renal Function
Study Start Date : October 2011
Actual Primary Completion Date : July 2014
Actual Study Completion Date : May 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Tests

Arm Intervention/treatment
Active Comparator: Cohort 1 Drug: E7389
Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
Other Name: Halaven

Active Comparator: Cohort 2 Drug: E7389
Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
Other Name: Halaven

Active Comparator: Cohort 3 Drug: E7389
Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
Other Name: Halaven

Primary Outcome Measures :
  1. To study the influence of moderate and severe renal impairment on the Composite of Pharmacokinetics of HALAVEN following a single intravenous administration to subjects with cancer. [ Time Frame: Halaven will be measured on Day 1 and 8 of a 21 day cycle. ]
    The primary analysis will be conducted using the dose-normalized primary PK parameters (AUC0-inf, AUC0-last, and Cmax) respectively. Relationships between each individual PK parameter and renal function (creatinine clearance) will be analyzed by linear regression models using the PK parameter as the dependent variable and renal function as the independent variable.

Secondary Outcome Measures :
  1. Number of Participants with Adverse Events as a Measure of Safety and Tolerability of HALAVEN in subjects with moderate or severe renal impairment, as well as in those with normal renal function. [ Time Frame: Halaven will be measured on Day 1 and 8 of a 21 day cycle. ]
    Safety data that will be evaluated include adverse events, clinical laboratory results, physical examination results, ECG, and vital signs

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed advanced solid tumors that have progressed following standard therapy or for which no standard therapy exists (including surgery or radiation therapy).
  • Renal function must fall into one of the following categories:
  • Normal function - creatinine clearance greater than or equal to 80 mL/min.
  • Moderate impairment - creatinine clearance >30 to 50 mL/min.
  • Severe impairment - creatinine clearance 15 to less than 30 mL/min.
  • Adequate liver function as evidenced by bilirubin less than or equal to 1.5 times the upper limit of normal (ULN) and alkaline phosphatase (ALP), alanine aminotransferase (ALT), and aspartate aminotransferase (AST) less than or equal to 3 times the ULN (in the case of liver metastasis less than or equal to 5 times ULN). In the case ALP >3 times the ULN (in the absence of liver metastasis) or >5 times the ULN (in the presence of liver metastasis), and the subject is also known to have bone metastasis, the liver specific ALP must be separated from the total and used to assess the liver function instead of the total ALP.

Exclusion Criteria:

  • Subjects with mild renal impairment (creatinine clearance greater than 50 to less than 80 mL/min).
  • Subjects with end stage renal disease (creatinine clearance less than 15 mL/min or on dialysis).
  • Subjects with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivatives.
  • Subjects with prior participation in an HALAVEN clinical study, even if not previously assigned to HALAVEN treatment.
  • Radiation therapy encompassing >30 % of bone marrow.
  • Subjects with organ allografts requiring immunosuppression.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01418677

Layout table for location information
United States, California
Duarte, California, United States
United States, Florida
Miami, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
United States, Michigan
Detroit, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Missouri
St. Louis, Missouri, United States
United States, New Jersey
New Brunswick, New Jersey, United States
United States, New York
Bronx, New York, United States
United States, Texas
San Antonio, Texas, United States
Sponsors and Collaborators
Eisai Inc.

Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Eisai Inc. Identifier: NCT01418677     History of Changes
Other Study ID Numbers: E7389-A001-106
First Posted: August 17, 2011    Key Record Dates
Last Update Posted: May 17, 2016
Last Verified: May 2016

Keywords provided by Eisai Inc.:
Unspecified Advance Solid Tumor, Protocol Specific

Additional relevant MeSH terms:
Layout table for MeSH terms
Renal Insufficiency
Kidney Diseases
Urologic Diseases